ERBB2 and breast cancer: Similarly, in metastatic BC, K-MASTER patients showed a higher incidence of HER2 + and TNBC-type tumors, accompanied by enrichments of TP53 and MSH6 mutations, while MSK-IMPACT patients exhibited a higher frequency of GATA3 mutations.